Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rapid Ebola Immunoassay From Corgenix Gains Authorization

This article was originally published in The Gray Sheet

Executive Summary

The firm's ReEBOV assay, which can deliver results within 15-25 minutes, is the first rapid test and immunoassay for the Ebola virus granted an emergency use authorization by FDA.

You may also be interested in...



The EU’s New Batteries Regulation: When And How Its Requirements Will Impact Medtech

The EU Batteries Regulation is yet another legal instrument medical device manufacturers must address over the coming years alongside the core Medical Device and IVD Regulations.

Mental Health Top Of Mind For Increasingly Health-Anxious Brits, Kaizo Survey Finds

Worryingly, however, British consumers are also increasingly turning to social media for health information, and rejecting it if it conflicts with what they believe, or if it is not based on personal experience. 

Kymera Puts Emphasis On Immunology In New Growth Phase

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel